# EDGAR Filing Document

**Accession Number:** 0001874252
**File Stem:** 0001213900-25-069660
**Filing Date:** 2025-7
**Character Count:** 2431
**Document Hash:** e35933f3e1ba1170ce3298c3a3a53592
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-069660.hdr.sgml**: 20250902

**ACCESSION NUMBER**: 0001213900-25-069660

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250731

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MAINZ BIOMED N.V.
- **CENTRAL INDEX KEY:** 0001874252
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** ROBERT KOCH STRASSE 50
- **CITY:** MAINZ
- **STATE:** 2M
- **ZIP:** 55129
- **BUSINESS PHONE:** 49 6131 5542860

**MAIL ADDRESS:**
- **STREET 1:** ROBERT KOCH STRASSE 50
- **CITY:** MAINZ
- **STATE:** 2M
- **ZIP:** 55129

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Mainz Biomed B.V.
- **DATE OF NAME CHANGE:** 20210721

**Mainz Biomed N.V.**

**Robert Koch Strasse 50**

**55129 Mainz**

**Germany**

July 31, 2025

**<u>VIA EDGAR</u>**

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

---

| | |
|:---|:---|
| **Re:** | **Mainz Biomed N.V.** |

---

**Registration Statement on Form F-1**

**File No. 333- 289095**

Ladies and Gentlemen:

The Company hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the "Securities Act"), acceleration of the effectiveness of the above-referenced Registration Statement so that such Registration Statement will become effective as of 8:00 am Eastern Time on Monday August 4, 2025, or as soon thereafter as practicable.

The Company understands that the Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Company is aware of its responsibilities under the Securities Act as they relate to the proposed public offering of the securities specified in the Registration Statement.

The undersigned respectfully requests that it be notified of the effectiveness of the above-referenced Registration Statement by telephone call to our counsel, Ortoli Rosenstadt LLP, by calling Tim Dockery at (212) 829-8946.

Very truly yours,

MAINZ BIOMED N.V.

---

| | |
|:---|:---|
| By: | /s/ William J. Caragol |
| Name: | William J. Caragol |
| Title: | Chief Financial Officer |

---